| Literature DB >> 28620464 |
Abstract
Maintaining synaptic integrity and function depends on the continuous removal and degradation of aged or damaged proteins. Synaptic protein degradation has received considerable attention in the context of synaptic plasticity and growing interest in relation to neurodegenerative and other disorders. Conversely, less attention has been given to constitutive, ongoing synaptic protein degradation and the roles canonical degradation pathways play in these processes. Here we briefly review recent progress on this topic and new experimental approaches which have expedited such progress and highlight several emerging principles. These include the realization that synaptic proteins typically have unusually long lifetimes, as might be expected from the remote locations of most synaptic sites; the possibility that degradation pathways can change with time from synthesis, cellular context, and physiological input; and that degradation pathways, other than ubiquitin-proteasomal-mediated degradation, might play key roles in constitutive protein degradation at synaptic sites. Finally, we point to the importance of careful experimental design and sufficiently sensitive techniques for studying synaptic protein degradation, which bring into account their slow turnover rates and complex life cycles.Entities:
Keywords: PKCλ; PKMζ; TS:YFP; autophagy; canonical degradation pathways; synaptic protein degradation; ubiquitin-proteasome system
Year: 2017 PMID: 28620464 PMCID: PMC5461898 DOI: 10.12688/f1000research.10599.1
Source DB: PubMed Journal: F1000Res ISSN: 2046-1402
Figure 1. Measuring the effects of catabolic inhibitors on synaptic protein degradation is challenged by the slow turnover rates of most synaptic proteins.
A) In a typical experiment, total protein content is measured (by Western blots, for example) following exposures to a pharmacological inhibitor (e.g. MG-132) of a degradation pathway (e.g. the ubiquitin-proteasome system [UPS]) for increasing durations. B) The fold-change is then plotted as a function of time, giving rise to plots such as that shown here. C) In the most simple view of synaptic protein metabolism, 1) protein synthesis occurs at a constant rate, 2) protein degradation occurs as a first-order reaction with a rate coefficient of where t ½ is the half-life of the protein of interest, 3) at steady state, the rate of protein synthesis is equal to the rate of protein degradation, resulting in constant protein concentrations, and 4) a pharmacological catabolic pathway inhibitor strongly reduces the degradation rate coefficient but does not affect the rate of protein synthesis. D) Under these assumptions, expected fold-changes in protein levels are shown for five proteins with increasingly longer half-lives. Note the minuscule changes for proteins with half-lives of 3 days or longer. The inhibitor is assumed to reduce the degradation rate coefficient by a factor of 20 (greater reductions do not significantly change these results). E) The expected fold-change in total protein content as a function of protein half-life is shown for three inhibition durations (4, 10, or 24 hours). The shaded region represents the half-lives of the majority of synaptic proteins for which half-life estimates were obtained in a prior study [32]. Note that even after inhibiting the catabolic pathway of interest for 24 hours, and even when assuming that protein synthesis rates are not reduced, expected changes in total synaptic protein amounts are very modest, raising a requirement for highly sensitive and accurate quantification methods and demonstrating the importance of prior knowledge regarding turnover rates for correctly interpreting results in such experiments.